Supernus Pharmaceuticals (SUPN) AI Stock Analysis

• Market Cap: $2.62B
• Dividend Yield: N/A
• Average Volume (3M): 955.54K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.62
• Revenue Growth: 4.54%
• EPS Growth: -130.59%
• Country: US
• Employees: 674
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.00
• Shares Outstanding: 57,339,350
• 10 Day Avg. Volume: 590,727
• 30 Day Avg. Volume: 955,536
• PEG Ratio: <0.01
• Price to Book (P/B): 1.92
• Price to Sales (P/S): 3.01
• P/FCF Ratio: 11.64
• Enterprise Value/Market Cap: 0.94
• Enterprise Value/Revenue: 3.61
• Enterprise Value/Gross Profit: 4.29
• Enterprise Value/Ebitda: 41.12
• 1Y Price Target: $60.50
• Price Target Upside: 32.44% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): 2.16
• Revenue Forecast (FY): $702.59M

• Rating: 55 Neutral
• Price Target: $48.00 ▲(5.08% Upside)

Supernus Pharmaceuticals demonstrates strong product growth and a stable balance sheet, but faces profitability and cash flow challenges. The technical analysis suggests potential for recovery, while valuation metrics are currently unattractive. The earnings call provided a positive outlook, but highlighted operational losses and supply issues.

Positive Factors

Revenue Growth

Consistent revenue growth reflects strong demand for Supernus's products, indicating successful market penetration and product adoption.

Product Performance

Strong performance of key products suggests robust demand and effective market strategies, supporting long-term revenue stability.

Financial Stability

A low debt-to-equity ratio enhances financial stability, providing flexibility for future investments and growth opportunities.

Negative Factors

Operating Losses

Significant operating losses can strain financial resources and impact profitability, necessitating cost management improvements.

Supply Constraints

Supply constraints hinder growth potential and customer satisfaction, requiring resolution to meet demand and sustain sales momentum.

Decreased Cash Reserves

Reduced cash reserves limit financial flexibility and may constrain the company's ability to invest in growth or manage unforeseen expenses.

Supernus Pharmaceuticals Business Overview & Revenue Model

Company Description

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system (CNS) disorders. The company primarily targets conditions such as epilepsy and attention-deficit hyperactivity disorder (ADHD) with a portfolio of proprietary products that include marketed drugs like Oxtellar XR and Trokendi XR. Supernus operates in the biopharmaceutical sector, leveraging its expertise in drug formulation and development to enhance treatment options for patients.

How the Company Makes Money

Supernus Pharmaceuticals generates revenue through the sale of its pharmaceutical products, which are primarily focused on CNS disorders. The company earns money by marketing its approved medications to healthcare providers and pharmacies, with a significant portion of its revenue coming from prescriptions filled by patients. In addition to direct sales, Supernus may also engage in partnerships or licensing agreements with other pharmaceutical companies to expand its market reach or enhance its product offerings. These partnerships can provide additional revenue streams through upfront payments, milestone payments, and royalties on sales of partnered products. Furthermore, the company's commitment to research and development may lead to new product launches that can contribute to future earnings.

Supernus Pharmaceuticals Financial Statement Overview

Summary

Supernus Pharmaceuticals shows strong revenue growth and a solid gross profit margin. However, it faces challenges with profitability and cash flow management. The balance sheet is stable with low leverage, but negative return on equity and cash flow issues suggest areas for improvement.

Income Statement

Supernus Pharmaceuticals shows a strong gross profit margin of over 90% in the TTM, indicating efficient production and sales processes. However, the company is currently experiencing negative net profit and EBIT margins, reflecting operational challenges and potential inefficiencies. The revenue growth rate is exceptionally high, suggesting a significant increase in sales, but the negative profitability metrics overshadow this growth.

Balance Sheet

The company's debt-to-equity ratio is low, indicating a conservative approach to leveraging, which is a positive sign of financial stability. However, the return on equity is negative in the TTM, highlighting concerns about the company's ability to generate returns for shareholders. The equity ratio is healthy, suggesting a strong capital base relative to assets.

Cash Flow

Operating cash flow is positive, but the operating cash flow to net income ratio is low, indicating potential issues in converting income into cash. The free cash flow growth rate is negative, suggesting challenges in maintaining cash reserves. However, the free cash flow to net income ratio is nearly 1, indicating efficient cash management relative to net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	681.54M	661.82M	607.52M	667.24M	579.77M	520.40M
Gross Profit	574.52M	583.91M	523.74M	580.02M	504.71M	467.94M
EBITDA	59.92M	178.28M	90.04M	153.36M	129.19M	210.54M
Net Income	-19.12M	73.86M	1.32M	60.71M	53.42M	126.95M
Balance Sheet
Total Assets	1.42B	1.37B	1.28B	1.70B	1.69B	1.50B
Cash, Cash Equivalents and Short-Term Investments	281.16M	453.61M	254.87M	461.33M	339.68M	422.53M
Total Debt	31.42M	34.27M	41.53M	444.76M	427.03M	414.32M
Total Liabilities	370.09M	332.34M	356.16M	816.30M	873.30M	759.24M
Stockholders Equity	1.05B	1.04B	921.52M	886.20M	815.85M	744.86M
Cash Flow
Free Cash Flow	132.54M	171.23M	110.53M	116.41M	125.08M	134.95M
Operating Cash Flow	133.54M	171.95M	111.08M	116.83M	127.13M	138.40M
Investing Cash Flow	-5.93M	-189.87M	268.73M	-216.66M	-81.91M	-34.70M
Financing Cash Flow	-14.57M	12.19M	-397.88M	-10.48M	-130.42M	3.56M

Supernus Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 45.68
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SUPN, the sentiment is Positive. The current price of 45.68 is above the 20-day moving average (MA) of 45.24, below the 50-day MA of 48.39, and above the 200-day MA of 38.55, indicating a neutral trend. The MACD of -1.01 indicates Negative momentum. The RSI at 45.87 is Neutral, neither overbought nor oversold. The STOCH value of 37.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SUPN.

Supernus Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMPH	79 Outperform	$1.23B	11.87	14.84%	―	-0.03%	-27.66%
ANIP	64 Neutral	$1.84B	50.15	7.83%	―	48.87%	―
AVDL	60 Neutral	$2.09B	―	-0.32%	―	79.88%	99.60%
SUPN	55 Neutral	$2.62B	―	-1.86%	―	4.54%	-130.59%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PRGO	49 Neutral	$1.85B	-35.68	-0.65%	8.63%	-2.55%	66.00%
ALVO	42 Neutral	$1.66B	23.84	―	―	55.38%	―

Supernus Pharmaceuticals Corporate Events

Supernus Faces Supply Constraints Amid High ONAPGO Demand

On November 4, 2025, Supernus Pharmaceuticals announced that due to stronger than expected demand for ONAPGO, supplier constraints are impacting the company’s ability to fully meet this demand. As a result, the company is prioritizing care for patients currently on ONAPGO by pausing delivery to new patients. The company is working to build adequate inventory and resume new patient initiations as soon as possible. Additionally, Supernus reported a 52% increase in combined revenues of its four growth products in the third quarter of 2025, driven by an increase in net sales of Qelbree and GOCOVRI, and the addition of sales from ZURZUVAE and ONAPGO. The company also completed the acquisition of Sage Therapeutics, Inc. on July 31, 2025, and increased its full-year 2025 revenue guidance.